XRpro Technology for the Detection and Evaluation of Carcinogens

用于检测和评估致癌物的 XRpro 技术

基本信息

批准号：
7908491
负责人：
Benjamin P Warner
金额：
$ 20万
依托单位：
ICAGEN, INC.
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-08-06 至 2012-08-05
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7908491
关键词：
Address Affinity Animals Antibodies Antioxidants Arsenic Binding Biological Biological Assay Biological Markers Blood Bromine Cadmium Carcinogenicity Tests Carcinogens Cell model Characteristics Chlorine Chromium Cleaved cell Color Cysteine Data Detection Development Dose Dyes Elements Evaluation Fluorescence Fluorescent Probes GAG Gene Goals Heavy Metals Human Human Papillomavirus Individual Information Systems International Agency for Research on Cancer Iodine Iron Lanthanoid Series Elements Lead Left Libraries Life Link Malignant Neoplasms Mass Spectrum Analysis Measurement Measures Mercury Metabolic Metabolic Biotransformation Metal exposure Metals Methionine Minerals Molecular National Toxicology Program Nickel Noise Pathway interactions Peptide aptamers Peptides Pesticide Residues Pharmacologic Substance Phase Phosphorus Phosphorylation Polychlorinated Biphenyls Process Production Protein Binding Proteins Protocols documentation R peptide Radioactive Reading Reagent Risk Role Sampling Screening procedure Selenium Shapes Signal Transduction Skin Cancer Slide Small Business Innovation Research Grant Specificity Specimen Sulfides Sulfur Technology Terbium Testing TimeLine Tissues Toxin Trypsin United States Environmental Protection Agency United States National Institutes of Health Urine Viral Proteins Zinc adduct aptamer cancer risk carcinogenesis fluorophore high risk high throughput screening melanoma member metal complex novel programs protein complex public health relevance selenoprotein stoichiometry toxic metal validation studies

项目摘要

DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. In Phase I, Caldera will demonstrate the feasibility of using its novel XRpro(R) technology to extract, concentrate, quantify, and characterize carcinogens from biological samples. This will also identify protein adduct biomarkers that are involved in critical carcinogenic and biotransformation pathways. This project addresses challenges listed in PA-09-187, including the measurement of carcinogens directly, without antibodies, dyes, tags, or radioactive materials. PUBLIC HEALTH RELEVANCE: Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. This project addresses challenges listed in PA-09-187, including the measurement of carcinogens directly, without antibodies, dyes, tags, or radioactive materials.

描述（由申请人提供）：Caldera Pharmaceuticals 将开发一组致癌物的定量生物标志物检测方法。在第一阶段，Caldera 将展示使用其新颖的 XRpro(R) 技术从生物样品中提取、浓缩、定量和表征致癌物的可行性。这还将鉴定参与关键致癌和生物转化途径的蛋白质加合物生物标志物。该项目解决了 PA-09-187 中列出的挑战，包括直接测量致癌物，无需抗体、染料、标签或放射性材料。公共健康相关性：Caldera Pharmaceuticals 将开发一组致癌物的定量生物标志物检测方法。该项目解决了 PA-09-187 中列出的挑战，包括直接测量致癌物，无需抗体、染料、标签或放射性材料。